In a phase I clinical trial of Navoximod (GDC-0919), an IDOi, in combination with the PD-L1 blocker, Atezolizumab, for the treatment of patients with advanced solid tumors, clinical efficacy was demonstrated at all dosage levels in all tumor types, including CC, with tolerable AEs. The gene discussed is CD274; the disease is neoplasm.